+

GB202304278D0 - Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy - Google Patents

Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy

Info

Publication number
GB202304278D0
GB202304278D0 GBGB2304278.1A GB202304278A GB202304278D0 GB 202304278 D0 GB202304278 D0 GB 202304278D0 GB 202304278 A GB202304278 A GB 202304278A GB 202304278 D0 GB202304278 D0 GB 202304278D0
Authority
GB
United Kingdom
Prior art keywords
chemotherapy
administration
combination
bispecific antibody
dosage regimens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2304278.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Star Therapeutics Ltd
Original Assignee
F Star Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Star Therapeutics Ltd filed Critical F Star Therapeutics Ltd
Priority to GBGB2304278.1A priority Critical patent/GB202304278D0/en
Publication of GB202304278D0 publication Critical patent/GB202304278D0/en
Priority to PCT/EP2024/057839 priority patent/WO2024194482A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2304278.1A 2023-03-23 2023-03-23 Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy Ceased GB202304278D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2304278.1A GB202304278D0 (en) 2023-03-23 2023-03-23 Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy
PCT/EP2024/057839 WO2024194482A1 (en) 2023-03-23 2024-03-22 Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2304278.1A GB202304278D0 (en) 2023-03-23 2023-03-23 Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy

Publications (1)

Publication Number Publication Date
GB202304278D0 true GB202304278D0 (en) 2023-05-10

Family

ID=86228115

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2304278.1A Ceased GB202304278D0 (en) 2023-03-23 2023-03-23 Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy

Country Status (2)

Country Link
GB (1) GB202304278D0 (en)
WO (1) WO2024194482A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3472207T1 (en) 2016-06-20 2021-04-30 F-Star Delta Limited Binding molecules that bind PD-L1 and LAG-3
CN114206939A (en) 2019-05-14 2022-03-18 F-星治疗有限公司 Dosage regimen for administration of LAG-3/PD-L1 bispecific antibodies

Also Published As

Publication number Publication date
WO2024194482A1 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
IL287979A (en) Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody
Hu et al. Recent advances of cocktail chemotherapy by combination drug delivery systems
WO2014186403A3 (en) Anti-folr1 immunoconjugate dosing regimens
MX388735B (en) COMBINATIONS OF AMISULPRIDE AND ANOTHER ANTI-EMETIC TO TREAT NAUSEA AND VOMITING.
SG11202108311RA (en) Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
SMT201500267B (en) DOSAGE REGULATION FOR THE ADMINISTRATION OF A BISPECIFIC ANTIBODY CD19XCD3
NZ598127A (en) Cancer metastasis inhibitor
AR095534A1 (en) INHIBITORS COMBINATIONS OF THE BRUTON TYROSINE QUINASE AND CYP3A4 INHIBITORS
SG10201907042PA (en) Anti-folr1 immunoconjugate dosing regimens
HUE063562T2 (en) Anti-IFNAR1 dosage regimen for subcutaneous injection
MX2020012755A (en) Anti-cd37 immunoconjugate dosing regimens.
GB202304278D0 (en) Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy
DK4025187T3 (en) DOSAGE REGIMES ASSOCIATED WITH EXTENDED-RELEASE INJECTABLE PALIPERIDONE FORMULATIONS
LT3946518T (en) Medication delivery device with gear set dosage system
IL315886A (en) Dosage regimens for anti-cd19 agents and uses thereof
IL308389A (en) Dosage regimens for ecubectedin
IL287443A (en) Dosage regimens for and compositions including anti-rsv antibodies
IL315178A (en) Dosage regimen
HUE065560T2 (en) Administration regimen of solutions of t4 thyroid hormone with high oral absorption
GB202006819D0 (en) Dosage regimen
IL308095A (en) Dosing regimens
PL4099986T3 (en) Xanthan-based ophthalmic topical formulations with a reduced dosage regimen
GB202306662D0 (en) Dosage regimen
EP4055061A4 (en) Dosage regimen for anti-egfrviii agents
GB202015771D0 (en) Dosage regimen

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载